Physician profile
Virginia Kellner
NPI 1407084528
$17,538.36
in general payments reported to CMS, 2019-2025
62 companies · $4,228 in 2025
The $4,228 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,212 · 2020: $1,915 · 2021: $1,933 · 2022: $884 · 2023: $2,012 · 2024: $3,354 · 2025: $4,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,384 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,383.66 |
| Education | $210.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,876.49 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,442.34 | 2021-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $945.06 | 2019-2025 | Nuplazid, Daybue |
| Teva Pharmaceuticals USA, INC. | $909.74 | 2019-2025 | Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $805.77 | 2019-2025 | Mavenclad |
| Allergan, INC. | $674.63 | 2019-2021 | |
| Ucb, INC. | $661.23 | 2019-2025 | Nayzilam, Briviact |
| Sunovion Pharmaceuticals INC. | $621.98 | 2019-2021 | |
| Lundbeck LLC | $616.94 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $605.68 | 2019-2025 | |
| Amgen INC. | $527.08 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $476.96 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $467.80 | 2023-2025 | |
| Biogen, INC. | $435.21 | 2019-2025 | Skyclarys, Vumerity, Tysabri |
| Neurelis, INC. | $403.53 | 2022-2025 | Valtoco |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Kellner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.